Jason Bennett

Jason Bennett

Auto-generated profile, based on publicly available information

Jason Bennett

Centre for Cell Signalling and Inflammation, Department of Medicine, Imperial College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Trends in Cell Biology
Verified
Journal Article
Closed access
LTLaura Tornatore
Laura Tornatore
ATAnil K. Thotakura
Anil K. Thotakura
JBJason Bennett
Jason Bennett
MMMarta Moretti
Marta Moretti
GFGuido Franzoso
Guido Franzoso

15 January 2014 in Nature Communications
Verified
Journal Article
Open access
GLGuang Sheng Ling
Guang Sheng Ling
JBJason Bennett
Jason Bennett
KWKevin J. Woollard
Kevin J. Woollard
MSMarta Szajna
Marta Szajna
LFLiliane Fossati-Jimack
Liliane Fossati-Jimack
MBMarina Botto
Marina Botto
Tuned and distinct responses of macrophages and dendritic cells to Toll-like receptor 4 (TLR4) activation induced by lipopolysaccharide (LPS) underpin the balance between innate and adaptive immunity. However, the molecule(s) that confer these cell-type-specific LPS-induced effects remain poorly understood. Here we report that the integrin αM (CD11b) positively regulates LPS-induced signalling pathways selectively in myeloid dendritic cells but not in macrophages. In dendritic cells, which express lower levels of CD14 and TLR4 than macrophages, CD11b promotes MyD88-dependent and MyD88-independent signalling pathways. In particular, in dendritic cells CD11b facilitates LPS-induced TLR4 endocytosis and is required for the subsequent signalling in the endosomes. Consistent with this, CD11b deficiency dampens dendritic cell-mediated TLR4-triggered responses in vivo leading to impaired T-cell activation. Thus, by modulating the trafficking and signalling functions of TLR4 in a cell-type-specific manner CD11b fine tunes the balance between adaptive and innate immune responses initiated by LPS.

1 February 2018 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Open access
JBJason Bennett
Jason Bennett
DCDaria Capece
Daria Capece
FBFederica Begalli
Federica Begalli
DVDaniela Verzella
Daniela Verzella
DDDaniel D’aNdrea
Daniel D’aNdrea
GFGuido Franzoso
Guido Franzoso
Constitutive NF-κB signalling has been implicated in the pathogenesis of most human malignancies and virtually all non-malignant pathologies. Accordingly, the NF-κB pathway has been aggressively pursued as an attractive therapeutic target for drug discovery. However, the severe on-target toxicities associated with systemic NF-κB inhibition have thus far precluded the development of a clinically useful, NF-κB-targeting medicine as a way to treat patients with either oncological or non-oncological diseases. This minireview discusses some of the more promising approaches currently being developed to circumvent the preclusive safety liabilities of global NF-κB blockade by selectively targeting pathogenic NF-κB signalling in cancer, while preserving the multiple physiological functions of NF-κB in host defence responses and tissue homeostasis.

22 August 2017 in Biomedicines
Verified
Journal Article
Open access
PDF file
FBFederica Begalli
Federica Begalli
JBJason Bennett
Jason Bennett
DCDaria Capece
Daria Capece
DVDaniela Verzella
Daniela Verzella
DDDaniel D'Andrea
Daniel D'Andrea
GFGuido Franzoso
Guido Franzoso
Transcription factors of the nuclear factor κB (NF-κB) family are central coordinating regulators of the host defence responses to stress, injury and infection. Aberrant NF-κB activation also contributes to the pathogenesis of some of the most common current threats to global human health, including chronic inflammatory diseases, autoimmune disorders, diabetes, vascular diseases and the majority of cancers. Accordingly, the NF-κB pathway is widely considered an attractive therapeutic target in a broad range of malignant and non-malignant diseases. Yet, despite the aggressive efforts by the pharmaceutical industry to develop a specific NF-κB inhibitor, none has been clinically approved, due to the dose-limiting toxicities associated with the global suppression of NF-κB. In this review, we summarise the main strategies historically adopted to therapeutically target the NF-κB pathway with an emphasis on oncology, and some of the emerging strategies and newer agents being developed to pharmacologically inhibit this pathway.

1 December 2012 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
MMMarta Moretti
Marta Moretti
JBJason Bennett
Jason Bennett
LTLaura Tornatore
Laura Tornatore
ATAnil K. Thotakura
Anil K. Thotakura
GFGuido Franzoso
Guido Franzoso

28 February 2018 in Cancer Research
Verified
Journal Article
Open access
PDF file
DVDaniela Verzella
Daniela Verzella
JBJason Bennett
Jason Bennett
MFMariafausta Fischietti
Mariafausta Fischietti
ATAnil K. Thotakura
Anil K. Thotakura
CRCamilla Recordati
Camilla Recordati
GFGuido Franzoso
Guido Franzoso
T-cell exclusion from the tumor microenvironment (TME) is a major barrier to overcoming immune escape. Here, we identify a myeloid-intrinsic mechanism governed by the NF-κB effector molecule GADD45β that restricts tumor-associated inflammation and T-cell trafficking into tumors. In various models of solid cancers refractory to immunotherapies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gadd45b inhibition in myeloid cells restored activation of proinflammatory tumor-associated macrophages (TAM) and intratumoral immune infiltration, thereby diminishing oncogenesis. Our results provide a basis to interpret clinical evidence that elevated expression of GADD45B confers poor clinical outcomes in most human cancers. Furthermore, they suggest a therapeutic target in GADD45β for reprogramming TAM to overcome immunosuppression and T-cell exclusion from the TME. Significance: These findings define a myeloid-based immune checkpoint that restricts T-cell trafficking into tumors, with potentially important therapeutic implications to generally improve the efficacy of cancer immunotherapy. Cancer Res; 78(5); 1275–92. ©2017 AACR.